


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO 		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			
<i>(use as many sheets as necessary)</i>			
Sheet	1	of	1
		Application Number	10/001,851
		Filing Date	November 20, 2001
		First Named Inventor	Rachel E. Meyers, et al.
		Group Art Unit	1635
		Examiner Name	James Schultz
		Attorney Docket Number	MP100-459PIRM

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Signature	WJ Security	Date Considered	12-20409

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		OCT 12 2004	Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Application Number	10/001,851
(use as many sheets as necessary)			Filing Date	November 20, 2001
Sheet	1	of	First Named Inventor	Rachael E. Meyers, et al.
			Group Art Unit	1635
			Examiner Name	James Schultz
			Attorney Docket Number	MPI00-459P1RM

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
ADS	CA	Hagen, F.K., et. al., "Caenorhabditis Elegans UDP-GalNAc:Polypeptide N-Acetylgalactosaminyltransferase GLY3 (gly-3) mRNA, Complete Cds", April 15, 1998 (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on October 4, 2004]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/ . GenBank Accession No. AF031833.	
	CB	Hagen, F.K., et. al., "Caenorhabditis Elegans UDP-GalNAc:Polypeptide N-Acetylgalactosaminyltransferase GLY4 (gly-4) mRNA, Complete Cds", April 15, 1998 (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on October 4, 2004]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/ . GenBank Accession No. AF031834.	
	CC	Hagen, F.K., et. al., "Caenorhabditis Elegans UDP-GalNAc:Polypeptide N-Acetylgalactosaminyltransferase GLY5a (gly-5) mRNA, Complete Cds", April 15, 1998 (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on October 4, 2004]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/ . GenBank Accession No. AF031835.	
	CD	Hagen, F.K., et. al., "Caenorhabditis Elegans UDP-GalNAc:Polypeptide N-Acetylgalactosaminyltransferase GLY5b (gly-5) mRNA, Complete Cds", April 15, 1998 (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on October 4, 2004]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/ . GenBank Accession No. AF031836.	
	CE	Hagen, F.K., et. al., "Caenorhabditis Elegans UDP-GalNAc:Polypeptide N-Acetylgalactosaminyltransferase GLY5c (gly-5) mRNA, Complete Cds", April 15, 1998 (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on October 4, 2004]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/ . GenBank Accession No. AF031837.	
	CF	Hagen, F.K., et. al., "Caenorhabditis Elegans UDP-GalNAc:Polypeptide N-Acetylgalactosaminyltransferase GLY6a (gly-6) mRNA, Complete Cds", April 15, 1998 (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on October 4, 2004]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/ . GenBank Accession No. AF031838.	
	CG	Hagen, F.K., et. al., "Caenorhabditis Elegans UDP-GalNAc:Polypeptide N-Acetylgalactosaminyltransferase GLY6b mRNA, Complete Cds", April 15, 1998 (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on October 4, 2004]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/ . GenBank Accession No. AF031839.	
	CH	Hagen, F.K., et. al., "Caenorhabditis Elegans UDP-GalNAc:Polypeptide N-Acetylgalactosaminyltransferase GLY6c (gly-6) mRNA, Complete Cds", April 15, 1998 (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on October 4, 2004]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/ . GenBank Accession No. AF031840.	
	CI	Hagen, F.K., et. al., "Caenorhabditis Elegans UDP-GalNAc:Polypeptide N-Acetylgalactosaminyltransferase Homolog GLY7 (gly-7) mRNA, Complete Cds", April 15, 1998 (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on October 4, 2004]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/ . GenBank Accession No. AF031841.	
	CJ	Hagen, F.K., et. al., "Caenorhabditis Elegans UDP-GalNAc:Polypeptide N-Acetylgalactosaminyltransferase Homolog GLY8 (gly-8) mRNA, Complete Cds", April 15, 1998 (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on October 4, 2004]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/ . GenBank Accession No. AF031842.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

James Schultz 12-20-04

Please type a plus sign (+) inside this box →

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0654-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p>Substitute for form 1449B/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(use as many sheets as necessary)</p>				Complete if Known												
				<table border="1"> <tr> <td>Application Number</td> <td>10/001,851</td> </tr> <tr> <td>Filing Date</td> <td>November 20, 2001</td> </tr> <tr> <td>First Named Inventor</td> <td>Rachel E. Meyers, et al..</td> </tr> <tr> <td>Group Art Unit</td> <td>1635</td> </tr> <tr> <td>Examiner Name</td> <td>James Schultz</td> </tr> <tr> <td>Attorney Docket Number</td> <td>MPI00-459PIRM</td> </tr> </table>	Application Number	10/001,851	Filing Date	November 20, 2001	First Named Inventor	Rachel E. Meyers, et al..	Group Art Unit	1635	Examiner Name	James Schultz	Attorney Docket Number	MPI00-459PIRM
Application Number	10/001,851															
Filing Date	November 20, 2001															
First Named Inventor	Rachel E. Meyers, et al..															
Group Art Unit	1635															
Examiner Name	James Schultz															
Attorney Docket Number	MPI00-459PIRM															
Sheet	2	of	4													

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPTIAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.		
WDS	CK	Hagen, F.K., et. al., "Caenorhabditis Elegans UDP-GalNAc:Polypeptide N-Acetylgalactosaminyltransferase Homolog GLY9 (gly-9) mRNA, Complete Cds", April 15, 1998 (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on October 4, 2004]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/ . GenBank Accession No. AF031843.		T ²
	CL	Isogai, T., et. al., "Homo Sapiens cDNA FLJ13720 fis, Clone PLACE2000438, Weakly Similar to Polypeptide N-Acetylgalactosaminyltransferase (EC 2.4.1.41)", January 30, 2004 (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on October 4, 2004]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/ . GenBank Accession No. AK023782.		
	CM	Sugano, S., et. al., "Homo Sapiens cDNA: FLJ21803 fis, Clone HEP00738", September 13, 2003 (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on October 4, 2004]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/ . GenBank Accession No. AK025456.		
	CN	NCBI Annotation Project, "Homo Sapiens KIAA0266 Gene Product (KIAA0266), mRNA", October 16, 2001, (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on October 4, 2004]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/ . GenBank Accession No. XM_012288.		
	CO	"Hypothetical Protein XP_012288 [Homo Sapiens], October 16, 2001, (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on October 4, 2004]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/ . GenBank Accession No. XP_012288.		
	CP	Homa, F.L., et al., "Polypeptide N-Acetylgalactosaminyltransferase 1 (Protein-UDP Acetylgalactosaminyltransferase 1) (UDP-GalNAc:Polypeptide N-Acetylgalactosaminyltransferase 1) (Polypeptide GalNAc Transferase 1) (GalNAc-T1) (pp-GaNTase 1) [Contains: Polypeptide N-Acetylgalactosaminyltransferase 1, Soluble Form]," created November 1, 1995 (sequence) GenPept [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on October 4, 2004]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/ . Swiss Prot Accession No. Q07537.		
	CQ	Meurer, J.A., et al., "Polypeptide N-Acetylgalactosaminyltransferase 1 (Protein-UDP Acetylgalactosaminyltransferase 1) (UDP-GalNAc:Polypeptide N-Acetylgalactosaminyltransferase 1) (Polypeptide GalNAc transferase 1) (GalNAc-T1) (pp-GaNTase 1) [Contains: Polypeptide N-Acetylgalactosaminyltransferase 1, Soluble Form]," created October 1, 1996 (sequence) GenPept [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on October 4, 2004]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/ . Swiss Prot Accession No. Q10472.		
	CR	Hagen, F.K., et al., "Polypeptide N-Acetylgalactosaminyltransferase 1 (Protein-UDP Acetylgalactosaminyltransferase 1) (UDP-GalNAc:Polypeptide N-Acetylgalactosaminyltransferase 1) (Polypeptide GalNAc transferase 1) (GalNAc-T1) (pp-GaNTase 1) [Contains: Polypeptide N-Acetylgalactosaminyltransferase 1, Soluble Form]," created October 1, 1996 (sequence) GenPept [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on October 4, 2004]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/ . Swiss Prot Accession No. Q10473.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

WJS 12-20-04

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
Sheet	3	of	4	Application Number	10/001,851
				Filing Date	November 20, 2001
				First Named Inventor	Rachel E. Meyers, et al.
				Group Art Unit	1635
				Examiner Name	James Schultz
				Attorney Docket Number	MPI00-459P1RM

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.				T ²
JD	CS	Bennett, E.P., et al., "Polypeptide N-Acetylgalactosaminyltransferase 3 (Protein-UDP Acetylgalactosaminyltransferase 3) (UDP-GalNAc:Polypeptide N-Acetylgalactosaminyltransferase 3) (Polypeptide GalNAc transferase 3) (GalNAc-T3) (pp-GaNTase 3)," created October 1, 2004 (sequence) GenPept [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on October 4, 2004]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/ . Swiss Prot Accession No. Q14435.				
	CT	Hagen, F.K., et al., "Probable N-Acetylgalactosaminyltransferase 9 (Protein-UDP Acetylgalactosaminyltransferase 9) (UDP-GalNAc:Polypeptide N-Acetylgalactosaminyltransferase 9) (pp-GaNTase 9)," created October 1, 2004 (sequence) GenPept [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on October 4, 2004]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/ . Swiss Prot Accession No. Q9U2C4.				
	CU	Adams, M.D., et al., "Polypeptide N-Acetylgalactosaminyltransferase 8 (Protein-UDP Acetylgalactosaminyltransferase 8) (UDP-GalNAc:Polypeptide N-Acetylgalactosaminyltransferase 8) (pp-GaNTase 8)," created October 1, 2004 (sequence) GenPept [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on October 4, 2004]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/ . Swiss Prot Accession No. Q9VUT6.				
	CV	Hagen, F.K., et al., "Polypeptide N-Acetylgalactosaminyltransferase 1 (Protein-UDP Acetylgalactosaminyltransferase 1) (UDP-GalNAc:Polypeptide N-Acetylgalactosaminyltransferase 1) (Polypeptide GalNAc transferase 1) (GalNAc-T1) (pp-GaNTase 1)," created October 16, 2001 (sequence) GenPept [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on October 4, 2004]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/ . Swiss Prot Accession No. Q08912.				
	CW	Yoshida, A., et al., "Polypeptide N-Acetylgalactosaminyltransferase 1 (Protein-UDP Acetylgalactosaminyltransferase 1) (UDP-GalNAc:Polypeptide N-Acetylgalactosaminyltransferase 1) (Polypeptide GalNAc transferase 1) (GalNAc-T1) (pp-GaNTase 1) [Contains: Polypeptide N-Acetylgalactosaminyltransferase 1, Soluble Form]," created October 16, 2001 (sequence) GenPept [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on October 4, 2004]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/ . Swiss Prot Accession No. Q29121.				
	CX	Schwientek, T., et al., "Polypeptide N-Acetylgalactosaminyltransferase 11 (Protein-UDP Acetylgalactosaminyltransferase 11) (UDP-GalNAc:Polypeptide N-Acetylgalactosaminyltransferase 11) (Polypeptide GalNAc transferase 11) (GalNAc-T11) (pp-GaNTase 11)," created October 1, 2004 (sequence) GenPept [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on October 5, 2004]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/ . Swiss Prot Accession No. Q8NCW6.				
↓	CY	Adams, M.D., et al., "Polypeptide N-Acetylgalactosaminyltransferase 2 (Protein-UDP Acetylgalactosaminyltransferase 2) (UDP-GalNAc:Polypeptide N-Acetylgalactosaminyltransferase 2) (pp-GaNTase 2)," created October 1, 2004 (sequence) GenPept [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on October 5, 2004]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/ . Swiss Prot Accession No. Q6WV19.				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

JD Schultz 12-20-04

Please type a plus sign (+) inside this box →

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0654-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
OCT 12 2004				Application Number	10/001,851
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Filing Date	November 20, 2001
(use as many sheets as necessary)				First Named Inventor	Rachel E. Meyers, et al..
Sheet	4	of	4	Group Art Unit	1635
				Examiner Name	James Schultz
				Attorney Docket Number	MPI00-459P1RM

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPTIAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.			T ²
JDS	CZ	Durbin, R., "Putative Polypeptide N-Acetylgalactosaminyltransferase 11 (Protein-UDP Acetylgalactosaminyltransferase 11) (UDP-GalNAc:Polypeptide N-Acetylgalactosaminyltransferase 11) (pp-GaNTase 11)," created October 1, 2004 (sequence) GenPept [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on October 5, 2004]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/ . Swiss Prot Accession No. Q7K755.			

Examiner Signature	<i>JDS Schultz</i>	Date Considered	12-20-04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.